NxStage Medical, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 33   

Articles published

NXTM 14.40 +0.36 (2.56%)
price chart
Commit To Purchase NxStage Medical At $12.50, Earn 14.1% Annualized Using ...
Investors considering a purchase of NxStage Medical Inc (Symbol: NXTM) stock, but cautious about paying the going market price of $13.65/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Related articles »  
NxStage Medical Inc.: NxStage� to Report Third Quarter 2014 Financial Results
LAWRENCE, Mass., Oct. 7, 2014 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, ...
Related articles »  
NxStage Announces FDA Clearance of Single Needle Technology
LAWRENCE, Mass., Sept. 16, 2014 /PRNewswire/ -- NxStage� Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite�, has received FDA clearance.
Related articles »  
Insider Selling: NxStage Medical President Sells 3550 Shares of Stock (NXTM)
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.11) by $0.01.
Insider Selling: Joseph E. Turk, Jr. Unloads 3550 Shares of NxStage Medical ...  Watch List News (press release)
Related articles »  
NxStage Patients Participate in 257-Mile Tour DaVita Bike Ride
LAWRENCE, Mass., Sept. 10, 2014 /PRNewswire/ -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to support four kidney failure patients performing home hemodialysis (HHD) treatment with the ...
Related articles »  
NxStage Medical Stock Rating Reaffirmed by Canaccord Genuity (NXTM)
NxStage Medical, Inc. logo Canaccord Genuity reaffirmed their buy rating on shares of NxStage Medical (NASDAQ:NXTM) in a report issued on Tuesday.
Canaccord Genuity Reaffirms Buy Rating for NxStage Medical (NXTM)  WKRB News
NxStage Medical President Sells $47357 in Stock (NXTM)  Intercooler
Related articles »  
Insider Selling: Joseph E. Turk, Jr. Sells 3550 Shares of NxStage Medical ...
Shares of NxStage Medical (NASDAQ:NXTM) opened at 13.06 on Monday. NxStage Medical has a 52 week low of $8.77 and a 52 week high of $15.65.
NxStage Medical CEO Jeffrey H. Burbank Unloads 2416 Shares (NXTM)
NxStage Medical logo NxStage Medical (NASDAQ:NXTM) CEO Jeffrey H. Burbank unloaded 2,416 shares of the company's stock on the open market in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $14.00, ...
Insider Selling: Jeffrey H. Burbank Unloads 2416 Shares of NxStage Medical ...  Intercooler
Related articles »  
Big Movers: Montage Technology Group Limited (NASDAQ:MONT), The Boeing ...
NxStage Medical, Inc. (Nasdaq:NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014, before the opening of the ...
NxStage Kidney Care Hosts Grand Opening Event at Florida Dialysis Center
LAWRENCE, Mass., Oct. 8, 2014 /PRNewswire/ -- NxStage� Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the grand opening of the company's South Orlando, Florida dialysis center.
Related articles »